Reply to "statin treatment for non-alcoholic steatohepatitis"

Journal of Hepatology

Volumn 64, Issue 1, 2016, Pages 242-243

  Dongiovanni, Paola ^a   Pihlajamaki, Jussi ^b   Romeo, Stefano ^c,d   Valenti, Luca ^a,d  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF EASTERN FINLAND   (Finland)

^c UNIVERSITY OF GOTHENBURG   (Sweden)

^d UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; FARNESOID X RECEPTOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ROSUVASTATIN;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DRUG INDICATION; HUMAN; LETTER; LIPOGENESIS; LIVER PROTECTION; NONALCOHOLIC FATTY LIVER; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); ALCOHOLIC FATTY LIVER; FATTY LIVER;

FATTY LIVER; FATTY LIVER, ALCOHOLIC; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; NON-ALCOHOLIC FATTY LIVER DISEASE;

EID: 84950983916     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2015.09.023     Document Type: Letter

References (7)

1. P. Dongiovanni, S. Petta, V. Mannisto, R. Margherita Mancina, R. Pipitone, V. Karja, and et al. Statin use and nonalcoholic steatohepatitis in at risk individuals J Hepatol 63 2015 705 712
2. P. Dongiovanni, B. Donati, R. Fares, R. Lombardi, R.M. Mancina, S. Romeo, and et al. PNPLA3 I148M polymorphism and progressive liver disease World J Gastroenterol 19 2013 6969 6978
3. R.M. Mancina, N. Matikainen, C. Maglio, S. Soderlund, N. Lundbom, A. Hakkarainen, and et al. Paradoxical dissociation between hepatic fat content and De Novo lipogenesis due to PNPLA3 sequence variant J Clin Endocrinol Metab 100 2015 E821 E825
4. C. Pramfalk, P. Parini, U. Gustafsson, S. Sahlin, and M. Eriksson Effects of high-dose statin on the human hepatic expression of genes involved in carbohydrate and triglyceride metabolism J Intern Med 269 2011 333 339
5. L. Eslami, S. Merat, R. Malekzadeh, S. Nasseri-Moghaddam, and H. Aramin Statins for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis Cochrane Database Syst Rev 12 2013 CD008623
6. V.G. Athyros, K. Tziomalos, T.D. Gossios, T. Griva, P. Anagnostis, K. Kargiotis, and et al. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis Lancet 376 2010 1916 1922
7. B.A. Neuschwander-Tetri, R. Loomba, A.J. Sanyal, J.E. Lavine, M.L. Van Natta, M.F. Abdelmalek, and et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial Lancet 385 2015 956 965